Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloproliferative disorders.

A J Bench1, N C Cross, B J Huntly

  • 1Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2XY, UK.

Best Practice & Research. Clinical Haematology
|October 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biology of primary breast cancer in older women beyond routine biomarkers.

Breast cancer (Tokyo, Japan)·2021
Same author

Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.

Oncogene·2021
Same author

Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.

Breast cancer research and treatment·2020
Same author

The OPTIMIZE patient- and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial.

Trials·2020
Same author

The Use of Figurative Language to Describe Frailty in Older Adults.

The Journal of frailty & aging·2018
Same author

The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis.

Breast cancer research : BCR·2018
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Myeloproliferative disorders (MPDs) involve abnormal blood cell growth. While lacking a single marker, chromosomal abnormalities in MPDs like polycythaemia vera indicate a poor prognosis.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myeloproliferative disorders (MPDs) are pre-leukaemic conditions characterized by the overproduction of myeloid lineages.
  • Unlike chronic myeloid leukaemia, MPDs lack a pathognomonic chromosomal abnormality.
  • Chromosomal abnormalities are observed in 30-40% of polycythaemia vera and idiopathic myelofibrosis cases, often correlating with a worse prognosis.

Purpose of the Study:

  • To investigate chromosomal abnormalities in myeloproliferative disorders.
  • To identify potential genetic targets and novel fusion proteins in MPDs.

Main Methods:

  • Analysis of chromosomal abnormalities in patients with polycythaemia vera, idiopathic myelofibrosis, and essential thrombocythaemia.
  • Molecular mapping of specific chromosomal deletions (20q, 13q).

Related Experiment Videos

  • Identification of fusion proteins in rare myeloproliferative syndromes.

    • Main Results:

    • Consistent acquired chromosomal changes in MPDs include del(20q), trisomy 8, trisomy 9, and duplication of 1q.
    • These abnormalities often originate in multipotent progenitor cells.
    • Molecular mapping has identified candidate genes for 20q and 13q deletions, and novel fibroblast growth factor receptor-1 fusion proteins have been identified.

    Conclusions:

    • Chromosomal abnormalities are significant in certain MPDs and can predict prognosis.
    • Further research into candidate genes and fusion proteins may reveal new therapeutic targets for MPDs.